Novartis Finance Chief Rules Out Large M&A
Two Thirds Of Mega-Mergers ‘Fail’
While the correction of the biotech markets downwards increases the chances of bolt-on deals, even with the reduced prices, interesting assets are not so easy to come by, so says Novartis CFO Harry Kirsch.
